Esther Vinarov represents hospitals, health systems, academic medical centers, digital health companies, physician group practices, pharmaceutical and medical device manufacturers, health care staffing agencies, and various other health care and life sciences companies.
Esther advises life sciences clients on issues associated with clinical research and the regulation of food, drugs, and medical devices by the Food and Drug Administration (FDA), including product promotion and advertising, good manufacturing practices, product recalls, FDA inspections, and enforcement actions. She provides regulatory and transactional due diligence support in food and life sciences M&A and other transactions and is involved in structuring various management service agreements and other arrangements to provide professional, practice management, or administrative services.
Esther counsels clients on regulatory and compliance issues, including direct-to-consumer telemedicine and telehealth, professional licensure, remote supervision, controlled substance prescribing, state corporate practice of medicine doctrines, and HIPAA (Health Insurance Portability and Accountability Act).
Esther maintains an active pro bono practice, representing clients in juvenile immigration proceedings and counseling various 501(c)(3) nonprofit organizations.
Esther is a member of the American Health Law Association and the Boston Bar Association.
Prior to attending law school, Esther studied clinical translation at a biomedical ethics research lab at McGill University. Her specific research focus was the impact of precision medicine on novel drug development in cancer.
Esther is coauthor of articles on oncology, drug developments in cancer, biomarker studies, and neurology that have appeared in leading medical journals.
Esperienze
- University of Michigan (J.D. 2021); McGill University (B.A. & Sc. 2016)
- Massachusetts